Essential Linsitinib, Igf-1r Kinase And Insr Kinase Inhibitor (tbi4814) Limited Time 95% Off [XTZFIKwm]

Linsitinib: IGF-1R and InsR Kinase Inhibitor

Introducing Linsitinib, a groundbreaking dual inhibitor designed for the targeted treatment of various cancers. This potent and selective compound is formulated to inhibit both insulin-like growth factor 1 (IGF-1R) kinase and insulin receptor (InsR) kinase, offering a multifaceted approach to cancer therapy. With its unique molecular structure and high purity (>98%), Linsitinib stands out as a reliable solution for researchers and healthcare professionals alike.

• High Potency: Linsitinib demonstrates exceptional activity against IGF-1R and InsR kinases, with IC50 values of 35 and 75 nM respectively, making it a highly effective inhibitor.
• Selective Targeting: The compound's selectivity ensures that it minimizes off-target effects, thereby enhancing its therapeutic efficacy and reducing potential side effects.

Product Specifications and Applications

Linsitinib, formally known as 3-[8-Amino-1-(2-phenyl-7-quinolyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutanol, is a powerful tool in the fight against cancer. It is also known as OSI-906 and has a molecular formula of C₂₆H₂₃N₅O, with a formula weight of 421.49. The product is supplied as a pure powder, soluble in DMSO (up to 30 mg/ml), and can be stored at -20°C for up to one year without losing its stability.

• Formulation: The powder form of Linsitinib ensures easy handling and precise dosing, making it a versatile choice for various research and clinical applications.
• Storage Stability: With a stability of ≥ 1 year, Linsitinib is a reliable and long-lasting product, minimizing the need for frequent reordering.

Practical Use and Benefits

Linsitinib's dual inhibitory action makes it a valuable asset in the development of combination therapies for various cancers. Its application procedures are straightforward, involving dissolution in DMSO followed by dilution to aqueous buffer. Solutions in DMSO can be stored at -20°C for up to two months, providing flexibility in usage and storage.

• Chemotherapeutic Potential: Linsitinib has shown promising results when used in combination with other drugs, offering new avenues for cancer treatment.
• Research Utility: The compound's properties make it an excellent choice for laboratory research, enabling scientists to delve deeper into the mechanisms of cancer and develop more effective treatments.